Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

Looking ahead to 2025, Moderna expects revenue of $1.5 to $2.5bn. Credit: Tada Images/Shutterstock. Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 – a sharp decline from the ...

Recordamos que fue el pasado mes de diciembre cuando la alcaldesa de Huesca recogía en Madrid el premio GreenWeek, una escultura con forma de baobab rodeado por una escalera infinita, al que ...

Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data The findings, published Tuesday in Nature, are important for another key reason. The team’s work originally ...

For the fourth time in five months, the Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other stocks. Ten companies kicked off this week’s trading with significant losses ...

Construction is now complete on the Moderna Innovation and Technology Centre (MITC), the pharma firm’s new research, development and manufacturing facility at Harwell Campus in Oxfordshire. Subject to ...

I initially rated Moderna as a SELL in mid-December, and despite a recent rally, the stock remains volatile. The news flow has been great in January, which mostly caused a rally in the stock.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...